News
By Martyn Williams
June 28, 2012 01:14 PM ET
IDG News Service - Lawyers for Samsung Electronics have petitioned a U.S. court to suspend a preliminary injunction that blocks its Galaxy Tab 10.1 tablet computer from sale in the country.
The South Korean electronics company filed papers on Wednesday at the U.S. District Court for the Northern District of California asking that the order be suspended pending an appeal.
The filing came a day after Judge Lucy Koh barred sales of the tablet and any "product that is no more than colorably different from this specified product and embodies any design contained in U.S. Design Patent No. D504,889."
Koh also ordered Apple to post a bond for $2.6 million toward any damages sustained by Samsung if the injunction is subsequently found to be erroneously enjoined.
Samsung argued the injunction on a number of points, including that Apple's evidence against the Galaxy Tab 10.1 is "seven months or older." Such injunctions are typically granted to prevent prospective harm from sales of the allegedly offending product, but that doesn't exist pending more current data from Apple, the company argued in the filing.
"Samsung not only has a strong likelihood of success on appeal given the Court's issuance of a preliminary injunction based on a stale record, but, absent a stay, the injunction will cause Samsung significant harm due to impaired relationships with customers and carriers, while causing no demonstrable injury to Apple," Samsung argued in its filing.
Samsung's appeal represents the latest round in a patent battle between the two companies that centers over a handful of patents covering product design.
Apple first asked for an injunction against the Galaxy Tab 10.1 in July last year. Koh denied the injunction in December, ruling that Apple was likely to suffer irreparable harm as a result of Samsung infringing the '889 design patent but that the patent itself was likely invalid.
The ruling ended up in the appeals court, which upheld Judge Koh's initial finding of infringement and irreparable harm with respect to the '889 Patent, but disagreed with her finding on the validity of the patent. That appeals court finding opened the door to this week's injunction.
Martyn Williams covers mobile telecoms, Silicon Valley and general technology breaking news for The IDG News Service. Follow Martyn on Twitter at @martyn_williams. Martyn's e-mail address is martyn_williams@idg.com
Reprinted with permission from IDG.net. Story copyright 2012 International Data Group. All rights reserved.
wisconsin recall election april 4 santa monica college wisconsin primary dallas fort worth airport texas tornados seattle seahawks new uniforms
Over 80 percent of people seek health-related information online, on everything from insurance to help diagnosing aches and pains. As the world goes mobile, so too does health. Instead of using Google for your health queries or perusing WebMD, 


Summer, it seems, has finally arrived.? And with it comes long lazy days at the beach, the pool? and, unfortunately, the associated risk of skin cancer. ?To guard against this we all know to limit sun exposure, use high factor sunscreen and seek shade. But now it seems there?s one more thing we can do to help safeguard ourselves ? take Advil!
Really? ? Yes, it would appear so. ?According to a case-control study published in the journal Cancer, the use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with reduced risk for skin cancer.
The risk reduction was seen in patients taking aspirin, NSAIDs, and COX-2 inhibitors, such as Celebrex.
So how do NSAIDs do it? ?The authors suggest that they reduce the risk of skin cancer by blocking COX enzymes, which are involved in the inhibition of apoptosis ?and in stimulating angiogenesis. Or, in plain English, these anti-inflammatory drugs counteract the enzymes involved in the important steps of cancer development such as inhibition of cell death and suppression of the immune system.
Nevertheless, when viewed alongside the study results?fom earlier this year that showed patients who took aspirin daily for at least three years were 36% less likely to develop metastatic cancer and 15% less likely to die from the disease, this can only be good news.








